2019 Fiscal Year Annual Research Report
シンチレーション粒子内包ナノカプセルの構築と放射線療法への展開
| Project/Area Number |
19F19068
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
宮田 完二郎 東京大学, 大学院工学系研究科(工学部), 准教授 (50436523)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAITI DEBABRATA 東京大学, 大学院工学系研究科, 外国人特別研究員
|
|---|
| Project Period (FY) |
2019-07-24 – 2021-03-31
|
| Keywords | photodynamic therapy / X ray / drug delivery / scintillator / photosensitizer |
|---|
| Outline of Annual Research Achievements |
The aim of this project is to design of biocompatible scintillating nanoparticles composed of scintillator (Sc) and photosensitizer (PS) for X-ray-induced photodynamic therapy for cancer treatment. In this formulation, Sc converts X-ray to light energy to activate PS, producing reactive oxygen species (ROS). To this end, terbium-doped NaYF4 (NaYF4:Tb) was fabricated as a Sc and conjugated with rose Bengal (RB) as a PS. We have successfully fabricted PS-loaded Sc nanoparticles and have completed their physicochemical characterizations, including dynamic light scattering, electrophoretic light scattering, transmission electron microscope (TEM) imaging, UV-visible absorbance measurement, and photoluminescence (PL) and X-ray radioluminescence measurement.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
当初予定していた通りのX線光力学療法のための機能性ナノ粒子を調製することができたため。
|
| Strategy for Future Research Activity |
We will continue biological characteristics to implement our ongoing research. In the beginning of the fiscal year, we will detect ROS in the presence of X-ray. We will use DCFH-DA assay to detect generation of ROS in an X-ray dose-dependent manner. More importantly, ROS-induced DNA damage and cell death will be examined by immunofluorescence stainning and CCK-8 assay kit, respectively. Then, the best formulation will be studied in vivo to evaluate the effective tumor accumulation after intravenous administration into subcutaneous breast tumor bearing balb/c mice. The tumor accumulation as injected dose (%) will be measured by inductively coupled plasma mass spectrometry (ICP-MS). Ultimately, the tumor will be irradiated by several X-ray dose to determine dose-dependent antitumor efficacy.
|
